Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat uterine cancer: targeted drug trial underway

NCT ID NCT06369155

Recruiting now Disease control Sponsor: Joyce Liu, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called azenosertib in 25 women with a rare and aggressive type of uterine cancer that has come back or not gone away. The goal is to see how the drug affects cancer cells and whether it can shrink tumors or slow the disease. Participants take the drug and have regular scans and biopsies to track results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma uterine cancer uterine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE CANCER UTERINE CARCINOMA UTERINE SEROUS CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact